Published in Blood on January 16, 2014
TET1 is a tumor suppressor of hematopoietic malignancy. Nat Immunol (2015) 2.44
Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Cell (2016) 2.10
Activating STAT6 mutations in follicular lymphoma. Blood (2014) 1.63
Chromatin signatures of cancer. Genes Dev (2015) 1.20
Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet (2016) 1.07
Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci U S A (2015) 1.03
SWI/SNF chromatin remodeling complexes and cancer. Am J Med Genet C Semin Med Genet (2014) 1.03
Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies. Mod Pathol (2016) 0.90
Methylation-independent repression of Dnmt3b contributes to oncogenic activity of Dnmt3a in mouse MYC-induced T-cell lymphomagenesis. Oncogene (2015) 0.87
Mutation of cancer driver MLL2 results in transcription stress and genome instability. Genes Dev (2016) 0.86
Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2. Proc Natl Acad Sci U S A (2016) 0.79
IRF4 and IRF8: Governing the virtues of B Lymphocytes. Front Biol (Beijing) (2014) 0.79
Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas. Blood Cancer J (2015) 0.79
A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma. Mod Pathol (2016) 0.78
Role of H1 linker histones in mammalian development and stem cell differentiation. Biochim Biophys Acta (2015) 0.78
Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. Blood (2016) 0.78
A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia. Clin Cancer Res (2016) 0.77
Loss of IRF8 Inhibits the Growth of Diffuse Large B-cell Lymphoma. J Cancer (2015) 0.77
Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies. Oncotarget (2016) 0.77
The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. Clin Cancer Res (2016) 0.77
Integrative whole-genome sequence analysis reveals roles of regulatory mutations in BCL6 and BCL2 in follicular lymphoma. Sci Rep (2017) 0.76
Recurrent somatic loss of TNFRSF14 in classical Hodgkin lymphoma. Genes Chromosomes Cancer (2015) 0.76
Mutational Analysis of Extranodal NK/T-Cell Lymphoma Using Targeted Sequencing with a Comprehensive Cancer Panel. Genomics Inform (2016) 0.75
Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma. Clin Cancer Res (2016) 0.75
The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP. Oncotarget (2017) 0.75
Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood (2016) 0.75
HIST1H1C Regulates Interferon-β and Inhibits Influenza Virus Replication by Interacting with IRF3. Front Immunol (2017) 0.75
Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma. Leukemia (2016) 0.75
Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations. Mod Pathol (2016) 0.75
The role of aberrant proteolysis in lymphomagenesis. Curr Opin Hematol (2015) 0.75
Epigenetic dysregulation in follicular lymphoma. Epigenomics (2015) 0.75
Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. Blood (2017) 0.75
Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. Nat Cell Biol (2017) 0.75
Linker Histone in Diseases. Int J Biol Sci (2017) 0.75
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet (2010) 10.97
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature (2011) 9.71
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood (2005) 8.37
Involvement of the bcl-2 gene in human follicular lymphoma. Science (1985) 8.19
Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci U S A (1985) 7.98
Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science (2008) 6.52
Histone H1 depletion in mammals alters global chromatin structure but causes specific changes in gene regulation. Cell (2005) 6.17
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20
The B-cell-specific Oct-2 protein contains POU box- and homeo box-type domains. Genes Dev (1988) 4.14
Crystal structure of the Oct-1 POU domain bound to an octamer site: DNA recognition with tethered DNA-binding modules. Cell (1994) 3.98
A human lymphoid-specific transcription factor that activates immunoglobulin genes is a homoeobox protein. Nature (1988) 3.95
CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature (2011) 3.72
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2013) 3.25
The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell (2011) 2.83
TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med (2009) 2.80
Molecular analysis of mbcl-2: structure and expression of the murine gene homologous to the human gene involved in follicular lymphoma. Cell (1987) 2.12
Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. N Engl J Med (1987) 1.94
Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood (2013) 1.86
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood (2013) 1.84
Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res (2010) 1.79
A mutation in the Icsbp1 gene causes susceptibility to infection and a chronic myeloid leukemia-like syndrome in BXH-2 mice. J Exp Med (2005) 1.74
Genetics of follicular lymphoma transformation. Cell Rep (2014) 1.70
Pathogenesis of follicular lymphoma. J Clin Invest (2012) 1.66
Molecular pathways in follicular lymphoma. Leukemia (2006) 1.53
Comprehensive analysis of copy number and allele status identifies multiple chromosome defects underlying follicular lymphoma pathogenesis. Clin Cancer Res (2007) 1.37
B cell development and immunoglobulin gene transcription in the absence of Oct-2 and OBF-1. Nat Immunol (2001) 1.33
The solution structure of the Oct-1 POU-specific domain reveals a striking similarity to the bacteriophage lambda repressor DNA-binding domain. Cell (1993) 1.33
Prognostic factors in follicular lymphoma. J Clin Oncol (2010) 1.31
IFN regulatory factor 8 restricts the size of the marginal zone and follicular B cell pools. J Immunol (2010) 1.22
Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma. Leukemia (2007) 1.17
6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma. Blood (1993) 1.16
High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis. Leukemia (2011) 1.14
Structure of the H1 C-terminal domain and function in chromatin condensation. Biochem Cell Biol (2011) 1.11
H1 linker histone promotes epigenetic silencing by regulating both DNA methylation and histone H3 methylation. Proc Natl Acad Sci U S A (2013) 1.08
Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes Chromosomes Cancer (2001) 1.07
Oct2 enhances antibody-secreting cell differentiation through regulation of IL-5 receptor alpha chain expression on activated B cells. J Exp Med (2008) 1.06
Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Discov (2011) 1.02
Clonal evolution in t(14;18)-positive follicular lymphoma, evidence for multiple common pathways, and frequent parallel clonal evolution. Clin Cancer Res (2008) 1.01
Cracking the enigmatic linker histone code. J Biochem (2008) 1.01
High incidence of chromosomal imbalances and gene amplifications in the classical follicular variant of follicle center lymphoma. Blood (1996) 1.01
High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy-neutral loss of heterozygosity and copy number alterations that target single genes. Genes Chromosomes Cancer (2010) 1.00
Functional long-range interactions of the IgH 3' enhancers with the bcl-2 promoter region in t(14;18) lymphoma cells. Oncogene (2008) 1.00
Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. Blood (2010) 0.98
Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. J Clin Oncol (2002) 0.96
Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer (2004) 0.94
Oct transcription factors mediate t(14;18) lymphoma cell survival by directly regulating bcl-2 expression. Oncogene (2006) 0.93
Pathology, pathogenesis and molecular genetics of follicular NHL. Best Pract Res Clin Haematol (2011) 0.89
Follicular lymphoma and the immune system: from pathogenesis to antibody therapy. Blood (2012) 0.87
Functional interplay between p53 acetylation and H1.2 phosphorylation in p53-regulated transcription. Oncogene (2012) 0.85
Delineation of a minimal region of deletion at 6q16.3 in follicular lymphoma and construction of a bacterial artificial chromosome contig spanning a 6-megabase region of 6q16-q21. Genes Chromosomes Cancer (2004) 0.84
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med (2007) 13.39
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med (2012) 6.99
The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch Gen Psychiatry (2011) 6.66
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol (2012) 6.20
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res (2006) 4.99
Long-term survival with glioblastoma multiforme. Brain (2007) 4.51
Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A (2008) 4.13
A multidimensional analysis of genes mutated in breast and colorectal cancers. Genome Res (2007) 4.09
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol (2009) 3.90
GAGE: generally applicable gene set enrichment for pathway analysis. BMC Bioinformatics (2009) 3.86
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol (2013) 3.77
Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med (2012) 3.67
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells (2007) 3.60
Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther (2006) 3.56
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood (2012) 3.44
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet (2012) 3.38
An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol (2009) 3.15
Targeting HIF1α eliminates cancer stem cells in hematological malignancies. Cell Stem Cell (2011) 2.80
Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board. Cancer (2006) 2.79
Intraoperative frozen section analysis of margins in breast conserving surgery significantly decreases reoperative rates: one-year experience at an ambulatory surgical center. Am J Clin Pathol (2012) 2.73
HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med (2010) 2.71
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood (2013) 2.65
HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host Microbe (2011) 2.59
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw (2010) 2.45
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res (2009) 2.44
Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol (2004) 2.42
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther (2010) 2.21
Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood (2007) 2.16
Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res (2007) 2.14
Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res (2011) 2.02
Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood (2010) 2.01
Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene (2005) 1.99
Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients. J Nucl Med (2003) 1.95
Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood (2008) 1.93
Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node. Ann Surg Oncol (2006) 1.75
Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res (2008) 1.74
Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region. J Am Chem Soc (2006) 1.68
The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer (2007) 1.64
Activating STAT6 mutations in follicular lymphoma. Blood (2014) 1.63
Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood (2012) 1.61
Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res (2009) 1.61
Antitumor reactivity of anti-CD3/anti-CD28 bead-activated lymphoid cells: implications for cell therapy in a murine model. J Immunother (2003) 1.60
A pathobiological role of the insulin receptor in chronic lymphocytic leukemia. Clin Cancer Res (2011) 1.54
Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification. Clin Cancer Res (2011) 1.50
Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer (2004) 1.50
Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol (2009) 1.47
Improving surgical outcomes for cancer in the United States. J Surg Oncol (2007) 1.47
Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. Surgery (2007) 1.47
Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl Med Biol (2009) 1.46
Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood (2011) 1.44
Peripheral primitive neuroectodermal tumor/Ewing's sarcoma of the craniospinal vault: case reports and review. Hum Pathol (2006) 1.43
A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy. J Nucl Med (2002) 1.42
Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res (2012) 1.39
131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling. J Nucl Med (2010) 1.38
[The results of open reduction through a medial approach for developmental dysplasia of the hip in children above 18 months of age]. Acta Orthop Traumatol Turc (2004) 1.38
Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. Cancer Res (2008) 1.38
Comprehensive analysis of copy number and allele status identifies multiple chromosome defects underlying follicular lymphoma pathogenesis. Clin Cancer Res (2007) 1.37
Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin Cancer Res (2012) 1.37
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol (2005) 1.35
Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res (2003) 1.35
Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera. J Proteome Res (2007) 1.32
Correlation of three-dimensional structures with the antibacterial activity of a group of peptides designed based on a nontoxic bacterial membrane anchor. J Biol Chem (2004) 1.30
Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J Proteome Res (2008) 1.29
Undifferentiated small round cell sarcoma with t(4;19)(q35;q13.1) CIC-DUX4 fusion: a novel highly aggressive soft tissue tumor with distinctive histopathology. Am J Surg Pathol (2013) 1.29
Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res (2009) 1.28
Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood (2010) 1.27
Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging (2014) 1.26
Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis. J Nucl Med (2012) 1.25
Immunologic response to cryoablation of breast cancer. Breast Cancer Res Treat (2005) 1.23
Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. Blood (2010) 1.23
18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med (2006) 1.22
Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res (2004) 1.22
The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res (2004) 1.22